189 related articles for article (PubMed ID: 34408176)
1. A potential bat adenovirus-based oncolytic virus targeting canine cancers.
Matsugo H; Kitamura-Kobayashi T; Kamiki H; Ishida H; Sekine W; Takenaka-Uema A; Nakagawa T; Murakami S; Horimoto T
Sci Rep; 2021 Aug; 11(1):16706. PubMed ID: 34408176
[TBL] [Abstract][Full Text] [Related]
2. Evolution and Cryo-electron Microscopy Capsid Structure of a North American Bat Adenovirus and Its Relationship to Other Mastadenoviruses.
Hackenbrack N; Rogers MB; Ashley RE; Keel MK; Kubiski SV; Bryan JA; Ghedin E; Holmes EC; Hafenstein SL; Allison AB
J Virol; 2017 Jan; 91(2):. PubMed ID: 27807242
[TBL] [Abstract][Full Text] [Related]
3. Preclinical Testing Oncolytic Vaccinia Virus Strain GLV-5b451 Expressing an Anti-VEGF Single-Chain Antibody for Canine Cancer Therapy.
Adelfinger M; Bessler S; Frentzen A; Cecil A; Langbein-Laugwitz J; Gentschev I; Szalay AA
Viruses; 2015 Jul; 7(7):4075-92. PubMed ID: 26205404
[TBL] [Abstract][Full Text] [Related]
4. Oncolysis of canine tumor cells by myxoma virus lacking the serp2 gene.
Urbasic AS; Hynes S; Somrak A; Contakos S; Rahman MM; Liu J; MacNeill AL
Am J Vet Res; 2012 Aug; 73(8):1252-61. PubMed ID: 22849686
[TBL] [Abstract][Full Text] [Related]
5. Establishment of a Simple and Efficient Reverse Genetics System for Canine Adenoviruses Using Bacterial Artificial Chromosomes.
Matsugo H; Kobayashi-Kitamura T; Kamiki H; Ishida H; Takenaka-Uema A; Murakami S; Horimoto T
Viruses; 2020 Jul; 12(7):. PubMed ID: 32708703
[TBL] [Abstract][Full Text] [Related]
6. Oncolytic virotherapy in veterinary medicine: current status and future prospects for canine patients.
Patil SS; Gentschev I; Nolte I; Ogilvie G; Szalay AA
J Transl Med; 2012 Jan; 10():3. PubMed ID: 22216938
[TBL] [Abstract][Full Text] [Related]
7. Anti-tumour activity of oncolytic Western Reserve vaccinia viruses in canine tumour cell lines, xenografts, and fresh tumour biopsies.
Autio K; Knuuttila A; Kipar A; Ahonen M; Parviainen S; Diaconu I; Kanerva A; Hakonen T; Vähä-Koskela M; Hemminki A
Vet Comp Oncol; 2016 Dec; 14(4):395-408. PubMed ID: 25302859
[TBL] [Abstract][Full Text] [Related]
8. Virotherapy of canine tumors with oncolytic vaccinia virus GLV-1h109 expressing an anti-VEGF single-chain antibody.
Patil SS; Gentschev I; Adelfinger M; Donat U; Hess M; Weibel S; Nolte I; Frentzen A; Szalay AA
PLoS One; 2012; 7(10):e47472. PubMed ID: 23091626
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic gene therapy for canine cancers: teaching old dog viruses new tricks.
Arendt M; Nasir L; Morgan IM
Vet Comp Oncol; 2009 Sep; 7(3):153-61. PubMed ID: 19691644
[TBL] [Abstract][Full Text] [Related]
10. Remission of Spontaneous Canine Tumors after Systemic Cellular Viroimmunotherapy.
Cejalvo T; Perisé-Barrios AJ; Del Portillo I; Laborda E; Rodriguez-Milla MA; Cubillo I; Vázquez F; Sardón D; Ramirez M; Alemany R; Del Castillo N; García-Castro J
Cancer Res; 2018 Sep; 78(17):4891-4901. PubMed ID: 29991502
[TBL] [Abstract][Full Text] [Related]
11. E1A, E1B double-restricted adenovirus with RGD-fiber modification exhibits enhanced oncolysis for CAR-deficient biliary cancers.
Wakayama M; Abei M; Kawashima R; Seo E; Fukuda K; Ugai H; Murata T; Tanaka N; Hyodo I; Hamada H; Yokoyama KK
Clin Cancer Res; 2007 May; 13(10):3043-50. PubMed ID: 17505007
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of an oncolytic measles virus against canine urinary bladder transitional cell carcinoma cells.
Iizuka K; Shoji K; Fujiyuki T; Moritoh K; Tamura K; Yoshida A; Sato H; Yoneda M; Asano K; Kai C
Res Vet Sci; 2020 Dec; 133():313-317. PubMed ID: 33183781
[TBL] [Abstract][Full Text] [Related]
13. Intratumoral Canine Distemper Virus Infection Inhibits Tumor Growth by Modulation of the Tumor Microenvironment in a Murine Xenograft Model of Canine Histiocytic Sarcoma.
Armando F; Fayyad A; Arms S; Barthel Y; Schaudien D; Rohn K; Gambini M; Lombardo MS; Beineke A; Baumgärtner W; Puff C
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33808256
[TBL] [Abstract][Full Text] [Related]
14. Oncolytic virotherapy of canine and feline cancer.
Gentschev I; Patil SS; Petrov I; Cappello J; Adelfinger M; Szalay AA
Viruses; 2014 May; 6(5):2122-37. PubMed ID: 24841386
[TBL] [Abstract][Full Text] [Related]
15. Dual E1A oncolytic adenovirus: targeting tumor heterogeneity with two independent cancer-specific promoter elements, DF3/MUC1 and hTERT.
Doloff JC; Jounaidi Y; Waxman DJ
Cancer Gene Ther; 2011 Mar; 18(3):153-66. PubMed ID: 20865021
[TBL] [Abstract][Full Text] [Related]
16. Combination of oncolytic adenovirus and endostatin inhibits human retinoblastoma in an in vivo mouse model.
Wang H; Wei F; Li H; Ji X; Li S; Chen X
Int J Mol Med; 2013 Feb; 31(2):377-85. PubMed ID: 23229955
[TBL] [Abstract][Full Text] [Related]
17. Telomerase-specific oncolytic virotherapy for human cancer with the hTERT promoter.
Fujiwara T; Urata Y; Tanaka N
Curr Cancer Drug Targets; 2007 Mar; 7(2):191-201. PubMed ID: 17346111
[TBL] [Abstract][Full Text] [Related]
18. A novel oncolytic adenovirus targeting Wnt signaling effectively inhibits cancer-stem like cell growth via metastasis, apoptosis and autophagy in HCC models.
Zhang J; Lai W; Li Q; Yu Y; Jin J; Guo W; Zhou X; Liu X; Wang Y
Biochem Biophys Res Commun; 2017 Sep; 491(2):469-477. PubMed ID: 28698142
[TBL] [Abstract][Full Text] [Related]
19. Permissiveness of human cancer cells to oncolytic bovine herpesvirus 1 is mediated in part by KRAS activity.
Cuddington BP; Mossman KL
J Virol; 2014 Jun; 88(12):6885-95. PubMed ID: 24696490
[TBL] [Abstract][Full Text] [Related]
20. Gene therapy targeting hepatocellular carcinoma by a dual-regulated oncolytic adenovirus harboring the focal adhesion kinase shRNA.
Gao Y; Zhu Y; Huang X; Ai K; Zheng Q; Yuan Z
Int J Oncol; 2015 Aug; 47(2):668-78. PubMed ID: 26081241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
